Background: Thyroid cancer is the most common endocrine type of malignancy, accounting for 1-5% of all cancers worldwide. Most of the differentiated thyroid cancers are asymptomatic. Surgery is the mainstay of management to be followed by radioactive iodine (RAI). RAI accessibility is still a challenge in most developing countries including Tanzania. The aim of this study was to determine factors affecting the clinical outcome of patients with differentiated thyroid cancer (DTC) following RAI treatment in a resource limited setting. Methods: This was a prospective cohort study carried out from 2014 to 2018 at the Ocean Road Cancer Institute, in Tanzania. A total of 52 histologically proven differentiated thyroid cancer patients post- near or total thyroidectomy were recruited. All patients received RAI therapy until ablation was achieved, were maintained on thyroxine suppression dose, and were followed for two years. Results: A total of 52 differentiated thyroid cancer patients were recruited after surgery by convenience sampling. The median age of patients was 46 years (range 17-77), and 87% (n=45) were female. Distant metastases were detected in 60% of patients (n=20) at initial presentation. The most common clinical presentation was a neck mass without compression symptoms (85%). Analysis at the end of two years revealed that female gender, clinical-pathological presentation, and the absence of distant metastasis(es) at diagnosis and amount of RAI received, contributed significantly to improved outcome. Conclusion: In a limited resource setting, the outcome of DTC patients post RAI therapy can be improved by early diagnosis hence improving clinical outcome.
| Published in | Cancer Research Journal (Volume 7, Issue 3) |
| DOI | 10.11648/j.crj.20190703.11 |
| Page(s) | 73-78 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2019. Published by Science Publishing Group |
Radioiodine Therapy, Thyroid Cancer, Tanzania
| [1] | Brown RL, de Souza JA, Cohen EE. Thyroid cancer: burden of illness and management of disease. J Cancer. 2011; 2: 193–9. |
| [2] | Iarc. IA for R on CWHO. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Globocan. 2012. |
| [3] | Schlumberger MJ. Papillary and Follicular Thyroid Carcinoma. N Engl J Med. 1998; 338 (5): 297–306. |
| [4] | Htwe TT, Hamdi MM, Swethadri GK, Wong JOL, Soe MM, Abdullah MS. Incidence of thyroid malignancy among goitrous thyroid lesions from the Sarawak General Hospital 2000-2004. Singapore Med J. 2009; 50 (7): 724–8. |
| [5] | Feldt-Rasmussen U. Iodine and Cancer. Thyroid. 2001; 11 (5): 483–6. |
| [6] | Andrews W, Kaiser DL. ThyroidCancer: Some BasicConsiderations. 1983; 33 (2): 87–97. |
| [7] | Handkiewicz-Junak D, Wloch J, Roskosz J, Krajewska J, Kropinska A, Pomorski L, et al. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer. J Nucl Med [Internet]. 2007; 48 (6): 879–88. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17536106 |
| [8] | Manel J, Blesa G, Pulido EG, Pulla MP, Candel VA, Bautista J, et al. Old and New Insights in the Treatment of Thyroid Carcinoma. 2010; 2010 (Table 1). |
| [9] | Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. CLINICAL REVIEW 170 A Systematic Review and Metaanalysis of the Effectiveness of Radioactive Iodine Remnant Ablation for Well-Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2004; 89 (8): 3668–76. |
| [10] | Silberstein EB, Alavi A, Balon HR, Clarke SEM, Divgi C, Gelfand MJ, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med [Internet]. 2012 Oct [cited 2014 Oct 13]; 53 (10): 1633–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22787108 |
| [11] | Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19: 1167–214. |
| [12] | Mazzaferri EL, Kloos RT. CLINICAL REVIEW 128 Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer. 2001; 86 (4): 1447–63. |
| [13] | Passler C, Scheuba C. Prognostic factors of papillary and follicular thyroid cancer: differences in an iodine-replete endemic goiter region. Endocrine-Related … [Internet]. 2004 [cited 2015 Jul 22]; 131–9. Available from: http://erc.endocrinology-journals.org/content/11/1/131.short |
| [14] | Wachter W, Mvungi M, Konig A, Pickardt CR, Scriba PC. Prevalence of goitre and hypothyroidism in Southern Tanzania: Effect of iodised oil on thyroid hormone deficiency. J Epidemiol Community Health. 1986. |
| [15] | Kalk WJ, Sitas F, Patterson AC. Thyroid cancer in South Africa--an indicator of regional iodine deficiency. S Afr Med J. 1997; 87 (6): 735–8. |
| [16] | Sirveaux F, Brunaud L, Klein M, Muresan MM, Olivier P, Lecle J. Bone metastases from differentiated thyroid carcinoma. 2008; 37–49. |
| [17] | Schlumberger MJ. Papillary and Follicular Thyroid Carcinoma. N Engl J Med. 1998; 338 (5): 297–306. |
| [18] | Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994. |
| [19] | Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JWA, Wiersinga W, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006. |
| [20] | Haugen BR, Kane MA. Approach to the thyroid cancer patient with extracervical metastases. Journal of Clinical Endocrinology and Metabolism. 2010. |
APA Style
Lulu Lunogelo Sakafu, Teddy Frank Mselle, Julius David Mwaiselage, Khamza Kibwana Maunda, Katherine Van Loon, et al. (2019). Factors Associated with Clinical Outcomes of Differentiated Thyroid Cancer Following Radioiodine Therapy in Tanzania. Cancer Research Journal, 7(3), 73-78. https://doi.org/10.11648/j.crj.20190703.11
ACS Style
Lulu Lunogelo Sakafu; Teddy Frank Mselle; Julius David Mwaiselage; Khamza Kibwana Maunda; Katherine Van Loon, et al. Factors Associated with Clinical Outcomes of Differentiated Thyroid Cancer Following Radioiodine Therapy in Tanzania. Cancer Res. J. 2019, 7(3), 73-78. doi: 10.11648/j.crj.20190703.11
AMA Style
Lulu Lunogelo Sakafu, Teddy Frank Mselle, Julius David Mwaiselage, Khamza Kibwana Maunda, Katherine Van Loon, et al. Factors Associated with Clinical Outcomes of Differentiated Thyroid Cancer Following Radioiodine Therapy in Tanzania. Cancer Res J. 2019;7(3):73-78. doi: 10.11648/j.crj.20190703.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.crj.20190703.11,
author = {Lulu Lunogelo Sakafu and Teddy Frank Mselle and Julius David Mwaiselage and Khamza Kibwana Maunda and Katherine Van Loon and Bouyoucef Salah Eddin},
title = {Factors Associated with Clinical Outcomes of Differentiated Thyroid Cancer Following Radioiodine Therapy in Tanzania},
journal = {Cancer Research Journal},
volume = {7},
number = {3},
pages = {73-78},
doi = {10.11648/j.crj.20190703.11},
url = {https://doi.org/10.11648/j.crj.20190703.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20190703.11},
abstract = {Background: Thyroid cancer is the most common endocrine type of malignancy, accounting for 1-5% of all cancers worldwide. Most of the differentiated thyroid cancers are asymptomatic. Surgery is the mainstay of management to be followed by radioactive iodine (RAI). RAI accessibility is still a challenge in most developing countries including Tanzania. The aim of this study was to determine factors affecting the clinical outcome of patients with differentiated thyroid cancer (DTC) following RAI treatment in a resource limited setting. Methods: This was a prospective cohort study carried out from 2014 to 2018 at the Ocean Road Cancer Institute, in Tanzania. A total of 52 histologically proven differentiated thyroid cancer patients post- near or total thyroidectomy were recruited. All patients received RAI therapy until ablation was achieved, were maintained on thyroxine suppression dose, and were followed for two years. Results: A total of 52 differentiated thyroid cancer patients were recruited after surgery by convenience sampling. The median age of patients was 46 years (range 17-77), and 87% (n=45) were female. Distant metastases were detected in 60% of patients (n=20) at initial presentation. The most common clinical presentation was a neck mass without compression symptoms (85%). Analysis at the end of two years revealed that female gender, clinical-pathological presentation, and the absence of distant metastasis(es) at diagnosis and amount of RAI received, contributed significantly to improved outcome. Conclusion: In a limited resource setting, the outcome of DTC patients post RAI therapy can be improved by early diagnosis hence improving clinical outcome.},
year = {2019}
}
TY - JOUR T1 - Factors Associated with Clinical Outcomes of Differentiated Thyroid Cancer Following Radioiodine Therapy in Tanzania AU - Lulu Lunogelo Sakafu AU - Teddy Frank Mselle AU - Julius David Mwaiselage AU - Khamza Kibwana Maunda AU - Katherine Van Loon AU - Bouyoucef Salah Eddin Y1 - 2019/07/23 PY - 2019 N1 - https://doi.org/10.11648/j.crj.20190703.11 DO - 10.11648/j.crj.20190703.11 T2 - Cancer Research Journal JF - Cancer Research Journal JO - Cancer Research Journal SP - 73 EP - 78 PB - Science Publishing Group SN - 2330-8214 UR - https://doi.org/10.11648/j.crj.20190703.11 AB - Background: Thyroid cancer is the most common endocrine type of malignancy, accounting for 1-5% of all cancers worldwide. Most of the differentiated thyroid cancers are asymptomatic. Surgery is the mainstay of management to be followed by radioactive iodine (RAI). RAI accessibility is still a challenge in most developing countries including Tanzania. The aim of this study was to determine factors affecting the clinical outcome of patients with differentiated thyroid cancer (DTC) following RAI treatment in a resource limited setting. Methods: This was a prospective cohort study carried out from 2014 to 2018 at the Ocean Road Cancer Institute, in Tanzania. A total of 52 histologically proven differentiated thyroid cancer patients post- near or total thyroidectomy were recruited. All patients received RAI therapy until ablation was achieved, were maintained on thyroxine suppression dose, and were followed for two years. Results: A total of 52 differentiated thyroid cancer patients were recruited after surgery by convenience sampling. The median age of patients was 46 years (range 17-77), and 87% (n=45) were female. Distant metastases were detected in 60% of patients (n=20) at initial presentation. The most common clinical presentation was a neck mass without compression symptoms (85%). Analysis at the end of two years revealed that female gender, clinical-pathological presentation, and the absence of distant metastasis(es) at diagnosis and amount of RAI received, contributed significantly to improved outcome. Conclusion: In a limited resource setting, the outcome of DTC patients post RAI therapy can be improved by early diagnosis hence improving clinical outcome. VL - 7 IS - 3 ER -
Information
Email: